Loading...
Uptake of screening and prevention in women at very high risk of breast cancer.
Evans, D Gareth R Lalloo, Fiona Shenton, Andrew Boggis, C Howell, Anthony
Evans, D Gareth R
Lalloo, Fiona
Shenton, Andrew
Boggis, C
Howell, Anthony
Citations
Altmetric:
Abstract
Management of women at high lifetime risk of familial breast cancer is hampered because of limited data concerning the appropriateness of treatment options. Over the past 8 years women at very high (>40%) lifetime risk of breast cancer have had the option of entering two chemoprevention treatment trials, a magnetic resonance imaging (MRI) breast screening study, or a risk-reducing mastectomy (RRM) study. Only 10% of eligible women have entered one of the chemotherapy trials with a similar proportion opting for RRM (>50% in mutation carriers) compared with 60% opting for MRI screening. Future chemotherapy trials will have to be designed to address this poor recruitment.
Affiliation
Description
Date
2001-09-15
Publisher
Collections
Keywords
Breast Cancer
Cancer Proteins
Cancer Proteins
Type
Article
Citation
Uptake of screening and prevention in women at very high risk of breast cancer. 2001, 358 (9285):889-90 Lancet